omniture
logo
Search
ONWARD THERAPEUTICS, INC.
Media Room

Latest News

rss

Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program

EPALINGES, Switzerland, Oct. 28, 2025 /PRNewswire/ -- Onward Therapeutics SA, a clinical stage onco...

2025-10-28 08:00 791

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ -- Onward Therapeutics SA, a biotechn...

2025-04-22 14:00 2011

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

EPALINGES, Switzerland and PARIS, Jan. 24, 2024 /PRNewswire/ -- Onward Therapeutics SA (Onward Ther...

2024-01-24 15:00 1840

Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapy

EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ -- Onward Therapeutics S...

2022-06-20 12:00 2302

Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier

EPALINGES, Switzerland, June 8, 2021 /PRNewswire/ -- Onward Therapeutics (Onward) and Institut du C...

2021-06-08 12:00 1702

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

LAUSANNE, Switzerland, Feb. 17, 2021 /PRNewswire/ -- Onward Therapeutics SA (Onward) announced toda...

2021-02-17 13:00 1863

Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology

Onward Also Makes an Equity Investment in Biomunex LAUSANNE, Switzerland, Feb. 16, 2021 /PRNewswi...

2021-02-16 13:00 2320